Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | CETP | P11597 | 3/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8933666 | 0.92 | TSHR (0.84) | TSHRBTN3A1SRCCETPPDPK1 | |
| Monoethanolamine SCHEMBL5459494 | 0.90 | TSHR (0.64) | TSHRBTN3A1SRCCETPPDPK1 | |
| SCHEMBL51316 | 0.88 | TSHR (1.00) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL27908642 | 0.88 | TSHR (1.00) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL6749263 | 0.87 | TSHR (0.75) | TSHRBTN3A1SRCCETPPDPK1 | |
| SCHEMBL4338628 | 0.86 | TSHR (0.62) | TSHRBTN3A1SRCCETPPDPK1 | |
| Hydrochloric Acid SCHEMBL10722992 | 0.86 | TSHR (0.96) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL9446520 | 0.86 | TSHR (0.96) | TSHRSRCCETPPDPK1MTOR | |
| Ammonia Solution, Strong SCHEMBL7268743 | 0.86 | TSHR (0.96) | TSHRSRCCETPPDPK1MTOR | |
| SCHEMBL4219700 | 0.86 | TSHR (0.96) | TSHRSRCCETPPDPK1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011045817-A2 | PROCESS FOR THE PREPARATION OF FOSAPREPITANT, INTERMEDIATE AND PHARMACEUTICAL ACCEPTABLE SALT THEREOF | SANDOZ PRIVATE LIMITED (IN) | 2011-04-21 | — | — | WO | claimed |
| EP-4733306-A1 | NOVEL MODIFIED TRINUCLEOTIDE CAPPING DERIVATIVE, AND MRNA INTO WHICH CAPPING DERIVATIVE IS INTRODUCED | Elonova Co., Ltd. (KR) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025129116-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025005647-A1 | NOVEL MODIFIED TRINUCLEOTIDE CAPPING DERIVATIVE, AND MRNA INTO WHICH CAPPING DERIVATIVE IS INTRODUCED | 전북대학교산학협력단 | 2025-01-02 | — | — | WO | disclosed |
| CN-119097698-A | Inhibitors of mevalonate pathway as efficient vaccine adjuvants | 清华大学 | 2024-12-10 | — | — | CN | disclosed |
| CN-114848656-B | Inhibitors of mevalonate pathway as efficient vaccine adjuvants | 清华大学 | 2024-09-27 | — | — | CN | disclosed |
| US-20240209010-A1 | PRODRUGS OF AZO COMPOUNDS AND THEIR SALTS | AMNEAL PHARMACEUTICALS LLC | 2024-06-27 | — | — | US | disclosed |
| CN-113527386-B | Intermediate of vaccine adjuvant MPLA, synthesis and application | 上海医药工业研究院 | 2024-03-29 | — | — | CN | disclosed |
| CN-113527396-B | Intermediate of vaccine adjuvant MPLA, synthesis and application | 上海医药工业研究院 | 2024-02-02 | — | — | CN | disclosed |
| CN-113527397-B | Intermediate of vaccine adjuvant MPLA, synthesis and application | 上海医药工业研究院 | 2024-02-02 | — | — | CN | disclosed |
| US-20110130366-A1 | FOSAPREPITANT DIMEGLUMINE INTERMEDIATE, NEUTRAL FOSAPREPITANT, AND AMORPHOUS FOSAPREPITANT DIMEGLUMINE AND PROCESSES FOR THEIR PREPARATIONS | GLENMARK GENERICS LMITED (IN) | 2011-06-02 | — | — | US | disclosed |
| WO-2011045817-A2 | PROCESS FOR THE PREPARATION OF FOSAPREPITANT, INTERMEDIATE AND PHARMACEUTICAL ACCEPTABLE SALT THEREOF | SANDOZ PRIVATE LIMITED (IN) | 2011-04-21 | — | — | WO | disclosed |
| EP-2303901-A2 | FOSAPREPITANT DIMEGLUMINE INTERMEDIATE, NEUTRAL FOSAPREPITANT, AND AMORPHOUS FOSAPREPITANT DIMEGLUMINE AND PROCESSES FOR THEIR PREPARATIONS | Glenmark Generics Limited (IN) | 2011-04-06 | — | — | EP | disclosed |
| EP-2279194-A1 | UNNATURAL POLYMERASE SUBSTRATES THAT CAN SUSTAIN ENZYMATIC SYNTHESIS OF DOUBLE STRANDED NUCLEIC ACIDS FROM A NUCLEIC ACID TEMPLATE AND METHODS OF USE | Life Technologies (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2010-05-27 | — | — | US | disclosed |
| EP-2155750-A2 | NEW IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | Mutabilis SA (FR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2010018595-A2 | FOSAPREPITANT DIMEGLUMINE INTERMEDIATE, NEUTRAL FOSAPREPITANT, AND AMORPHOUS FOSAPREPITANT DIMEGLUMINE AND PROCESSES FOR THEIR PREPARATIONS | GLENMARK GENERICS LIMITED (IN) | 2010-02-18 | — | — | WO | disclosed |
| WO-2009134469-A1 | UNNATURAL POLYMERASE SUBSTRATES THAT CAN SUSTAIN ENZYMATIC SYNTHESIS OF DOUBLE STRANDED NUCLEIC ACIDS FROM A NUCLEIC ACID TEMPLATE AND METHODS OF USE | LIFE TECHNOLOGIES (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090269759-A1 | UNNATURAL POLYMERASE SUBSTRATES THAT CAN SUSTAIN ENZYMATIC SYNTHESIS OF DOUBLE STRANDED NUCLEIC ACIDS FROM A NUCLEIC ACID TEMPLATE AND METHODS OF USE | LIFE TECHNOLOGIES (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2008117225-A2 | NEW IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | DLAT, DLST, DNTT | TSHR 3930/4885BTN3A1 2144/4885SRC 3992/4885 |
| US-20110130366-A1 | FOSAPREPITANT DIMEGLUMINE INTERMEDIATE, NEUTRAL FOSAPREPITANT, AND AMORPHOUS FOSAPREPITANT DIMEGLUMINE AND PROCESSES FOR THEIR PREPARATIONS | HRH2, CMA1, TPSD1 | TSHR 2944/4885BTN3A1 4561/4885SRC 4282/4885 |
| US-20090269759-A1 | UNNATURAL POLYMERASE SUBSTRATES THAT CAN SUSTAIN ENZYMATIC SYNTHESIS OF DOUBLE STRANDED NUCLEIC ACIDS FROM A NUCLEIC ACID TEMPLATE AND METHODS OF USE | RNGTT, UNG, POLRMT | TSHR 3849/4885BTN3A1 3175/4885SRC 4791/4885 |
| US-20240209010-A1 | PRODRUGS OF AZO COMPOUNDS AND THEIR SALTS | CYP11B1, CYP2C19, CYP11B2 | TSHR 3565/4885BTN3A1 4358/4885SRC 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.